



Article scientifique

Article

2023

Published version

Public access

This is the published version of the publication, made available in accordance with the publisher's policy.

Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study

Tancredi, Stefano; Chiolero, Arnaud; Wagner, Cornelia; Haller, Moa Lina; Chocano-Bedoya, Patricia; Ortega, Natalia; Rodondi, Nicolas; Kaufmann, Laurent; Lorthe, Elsa Louise Adèle; Baysson, Hélène; Stringhini, Silvia; Michel, Gisela; Lüdi, Chantal; Harju, Erika [and 22 more]

Collaborators: Azman, Andrew; Bals, Antoine; Bleich, Patrick; Bryand, Gaëlle; Collombet, Prune; D'ippolito, Paola; Dubos, Richard; Dumont, Roxane Dina Caroline; El Merjani, Nacira; Flahault, Antoine; Francioli, Natalie; Frangville, Marion Graindorge, Clément [and 20 more]

How to cite

TANCREDI, Stefano et al. Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study. In: *Infection*, 2023, vol. 51, n° 5, p. 1453–1465. doi: 10.1007/s15010-023-02011-0

This publication URL: <https://archive-ouverte.unige.ch/unige:177489>

Publication DOI: [10.1007/s15010-023-02011-0](https://doi.org/10.1007/s15010-023-02011-0)



Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study

Stefano Tancredi¹ · Arnaud Chiolero^{1,2,3} · Cornelia Wagner¹ · Moa Lina Haller^{3,4} · Patricia Chocano-Bedoya^{1,3} · Natalia Ortega^{1,3} · Nicolas Rodondi^{3,4} · Laurent Kaufmann⁵ · Elsa Lorthe⁶ · H el ene Baysson^{6,7} · Silvia Stringhini^{6,7,8} · Gisela Michel⁹ · Chantal L udi⁹ · Erika Harju^{9,10} · Irene Frank¹⁰ · Medea Imboden^{11,12} · Melissa Witzig^{11,12} · Dirk Keidel^{11,12} · Nicole Probst-Hensch^{11,12} · Rebecca Amati¹³ · Emiliano Albanese¹³ · Laurie Corna¹⁴ · Luca Crivelli¹⁴ · Julia Vincentini¹⁵ · Semira Gonseth Nussl e¹⁵ · Murielle Bochud¹⁵ · Val erie D’Acremont^{11,15} · Philipp Kohler¹⁶ · Christian R. Kahlert^{16,17} · Alexia Cusini¹⁸ · Anja Frei¹⁹ · Milo A. Puhan¹⁹ · Marco Geigges¹⁹ · Marco Kaufmann¹⁹ · Jan Fehr¹⁹ · St ephane Cullati^{1,20} on behalf of the Corona Immunitas Research Group

Received: 15 November 2022 / Accepted: 22 February 2023 / Published online: 4 March 2023
  The Author(s) 2023

Abstract

Purpose We aimed to assess the seroprevalence trends of SARS-CoV-2 antibodies in several Swiss cantons between May 2020 and September 2021 and investigate risk factors for seropositivity and their changes over time.

Methods We conducted repeated population-based serological studies in different Swiss regions using a common methodology. We defined three study periods: May–October 2020 (period 1, prior to vaccination), November 2020–mid-May 2021 (period 2, first months of the vaccination campaign), and mid-May–September 2021 (period 3, a large share of the population vaccinated). We measured anti-spike IgG. Participants provided information on sociodemographic and socioeconomic characteristics, health status, and adherence to preventive measures. We estimated seroprevalence with a Bayesian logistic regression model and the association between risk factors and seropositivity with Poisson models.

Results We included 13,291 participants aged 20 and older from 11 Swiss cantons. Seroprevalence was 3.7% (95% CI 2.1–4.9) in period 1, 16.2% (95% CI 14.4–17.5) in period 2, and 72.0% (95% CI 70.3–73.8) in period 3, with regional variations. In period 1, younger age (20–64) was the only factor associated with higher seropositivity. In period 3, being aged ≥ 65 years, with a high income, retired, overweight or obese or with other comorbidities, was associated with higher seropositivity. These associations disappeared after adjusting for vaccination status. Seropositivity was lower in participants with lower adherence to preventive measures, due to a lower vaccination uptake.

Conclusions Seroprevalence sharply increased over time, also thanks to vaccination, with some regional variations. After the vaccination campaign, no differences between subgroups were observed.

Keywords COVID-19 pandemic · SARS-CoV-2 · Seroprevalence · Epidemiology · Public health · Surveillance

Introduction

An accurate description of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread dynamics is key to informing and driving policymakers’ decisions.

The members of the institutional author group “the Corona Immunitas Research Group” was processed under acknowledgements section.

✉ Stefano Tancredi
stefano.tancredi@unifr.ch

Extended author information available on the last page of the article

Yet, surveillance based on PCR or antigen-reported cases resulted in biased estimates of the virus spread [1] due to a large share of a- or pauci-symptomatic infections [2, 3], changes in care-seeking behaviours, and different screening and diagnostic strategies across regions and over time. For instance, when SARS-CoV-2 first emerged, many European countries had limited testing capacities [4], and some, including Switzerland, restricted testing to patients admitted to hospitals. This led to a surveillance bias [5], with an underestimation of the number of SARS-CoV-2 cases. By contrast, serological studies account for all infections,

providing a more representative, albeit less timely, picture of the extent and dynamics of the COVID-19 pandemic.

So far, many SARS-CoV-2 seroprevalence studies have been conducted, both in the general population and in specific subgroups, to monitor the pandemic and inform on population levels of immunity [6–8]. A recent literature review [9] showed substantial worldwide geographical variability in seroprevalence estimates, caused by differences in the extent of infections and vaccination coverage. It also showed evidence of considerable infection under-ascertainment, highlighting the importance of seroprevalence estimates to describe the true number of SARS-CoV-2 infections. However, variabilities in research designs, tests used, or studies quality and reporting, make it challenging to compare estimates between countries or between regions within the same country. In addition to their role in assessing immunity levels and monitoring the virus's spread, seroepidemiological studies are also a strong tool to understand the drivers of the spread and to identify groups at higher risk of infection. During the pandemic, many factors have been linked to increased seropositivity, including socioeconomic, sociodemographic, or health characteristics. A higher exposure to SARS-CoV-2 is possible in socioeconomically disadvantaged individuals [10] (e.g., with a lower income or lower educational level), and differences in exposure have been found in different age groups [11, 12] or according to job type, health behaviours (e.g., smokers versus non-smokers) or health characteristics (e.g., with respect to different BMI levels or number of comorbidities) [11, 13, 14]. Additionally, the evidence suggests that different levels of stringency of mitigation policies [9] and adherence to preventive measures were also associated with seropositivity [15]. However, countries experienced a wide range of different epidemiological situations; governments recommendations and individual behaviours changed, and vaccines have been rolled out. It is therefore likely that factors associated with seropositivity have also changed over time.

In Switzerland, the Swiss School of Public Health (SSPH+) launched in the early phases of the pandemic the Corona Immunitas research program [16], implementing repeated population-based seroprevalence studies, with the aim of estimating the proportion of the population who developed anti-SARS-CoV-2 antibodies over time. Conducting repeated studies using a common methodology, at regular intervals, and with shared coordination, offers unique strengths to provide a clear picture of the population immunological status over time and across regions, and allows investigating trends in seroprevalence of SARS-CoV-2 antibodies, making comparisons between regions, and investigating differences in the virus's exposure between different populations' groups. In light of the above, using data from Corona Immunitas, we aimed to (1) assess the seroprevalence trends of SARS-CoV-2 antibodies in Switzerland

between May 2020 and September 2021, both at a quasi-national and cantonal level (descriptive aim), and (2) investigate risk factors for seropositivity and their changes over time (etiologic aim).

Methods


Study design

This study is part of Corona Immunitas [16]. Repeated population-based serological studies were conducted in different regions of Switzerland. Testing periods could change for each participating site. Invited participants were randomly selected from the national residential registry by the Swiss Federal Statistical Office for each new assessment wave; 65,500 participants were invited, the average participation rate was around 21%, with regional differences (from 16 to 39%). For this study, we defined three study periods: period 1 from May 2020 to October 2020 (before the launch of the vaccination campaign in Switzerland), period 2 from November 2020 to mid-May 2021 (in the first months of the vaccination campaign), and period 3 from mid-May 2021 to September 2021 (a significant share of the population vaccinated). Each period corresponds to a time window following each of the first three pandemic waves in Switzerland (Fig. 1). This choice was made because estimating seroprevalence after each epidemic wave was deemed more informative for descriptive purposes, and it is in line with the World Health Organization (WHO) recommendations for cross-sectional seroprevalence studies [17]. At each period, participants provided a venous blood sample and filled out a questionnaire on demographic and socioeconomic characteristics, adherence to COVID-19 preventive measures, health status and, once available, vaccination status. The questionnaire could be completed either in person or online (data were collected using REDCap, Research Electronic Data Capture) [18].

Study population

We included 13,291 participants (in period 1 $n = 3402$, in period 2 $n = 5611$, and in period 3 $n = 4278$) aged 20 and older from 11 Swiss cantons (Additional file1: Fig. S1). Around 5.9 million people live in these cantons, that is roughly 68% of the entire Swiss population. Those aged below 65-years of age and those above were sampled in a ratio of 1:1, with few exceptions in some cantons where only one age group has been recruited. For the second objective of this study, we excluded participants who completed the questionnaire more than 30 days before or after having provided the blood sample for the serology test. The reason for this exclusion was to avoid a possible mismatch between

Fig. 1 Blood samplings per week and daily confirmed COVID-19 cases reported in Switzerland, May 2020–September 2021



Note: In green, daily new COVID-19 cases per million people in Switzerland; 7-day rolling average. In blue, number of Corona Immunitas blood samplings per week

serology results and information reported in the questionnaires (preventive behaviours, health status and socioeconomic status). For the same reason, we also excluded participants who provided information on vaccination status more than 11 days before or after providing the blood sample for the serology test. Figure S2 (Additional file 1: Fig. S2) shows a flow diagram of the participants included in the study for each study objective.

Testing procedure

We analysed venous blood samples using the SenASTrIS assay, developed by the Vaud Central University Hospital (CHUV), the Swiss Federal Institute of Technology in Lausanne (EPFL) and the Swiss Vaccine Center [19]. The assay measures the amount of human immunoglobulins G (IgG) that binds the trimeric SARS-CoV-2 spike protein, induced either by infection or vaccination. The test was validated on a sample of the general population and specificity and sensitivity were 99.7% and 96.6% for the detection of IgG antibodies. Borderline test results (i.e., a signal just below the predefined cut-off) were categorized as seronegative ($n = 140$, 1%). A detailed description of the test is available elsewhere [19].

Potential risk factors

For the second objective of this study, we investigated the following potential risk factors, selected based on findings of previous studies, background expert knowledge and a priori reasons for having an increased risk of being seropositive [10, 11, 13, 14, 20–22]: sex, age (20–64 years old

vs 65 years and older), educational level (primary, secondary, tertiary), body mass index (BMI; < 18.5 ; 18.5 – 24.9 ; 25 – 29.9 , ≥ 30 kg/m^2), household monthly income (≤ 3000 CHF, > 3000 – 6000 CHF, > 6000 – 9000 CHF, > 9000 CHF; 1 Euro equalled 1.046 to 1.112 CHF between 1st January 2020 and 25th November 2021), employment status (retired, outside the labour force, self-employed, employed), number of children in the household (none, one child, two or more children), comorbidity score (0, 1, ≥ 2), smoking habit (current smokers vs non-smokers; former smokers were included in the non-smokers category), physical distancing during the previous seven days (frequently, occasionally/rarely), staying at home during the previous seven days (frequently, occasionally/rarely), wearing a mask during the previous seven days (frequently, occasionally/rarely), hygiene measures during the previous seven days (frequently, occasionally/rarely). BMI was categorized according to the World Health Organization standard categories [23]. Educational level was categorized according to the International Standard Classification of Education (ISCED). Physical distancing, staying at home and hygiene measures' variables were defined as having implemented the measures recommended by public health authorities (e.g.: keeping a distance of 1.5 m, staying at home whenever possible, avoiding unnecessary activities outside the home, no handshaking or hugging, washing hands regularly, sneezing into the elbow, using tissues, etc.). The comorbidity score goes from 0 to ≥ 2 and was calculated using the following possible answers (one point for each disease) to the question “Do you suffer from one or more of the following diseases?”: cancer, immunological diseases, cardiovascular diseases, diabetes, hypertension, respiratory diseases and allergies.

Statistical analysis

To estimate seroprevalence (objective 1), we used a Bayesian logistic regression model, adjusted for the antibody test sensitivity and specificity performances [24]. Seroprevalence estimates were weighted by the age and sex distribution of the population of each canton. We investigated the association between potential risk factors and seropositivity (objective 2) using Poisson regression models and expressed as prevalence ratios (PR) and 95% confidence intervals. Robust variance estimators were used to relax the assumption that the outcome distribution followed a Poisson distribution. Sex, age, educational level, BMI, income, employment status, number of children in the household, comorbidity score and smoking habit were included in the models (hereafter, model 1). Results were stratified by study period. Models for period 3 were adjusted for vaccination status (hereafter, model 2; in Switzerland the vaccination campaign started at the end of December 2020, during the second period of this study). To investigate seropositivity risk factors and their changes over time (objective 2), we used multiple imputation by chained equations to impute any missing data (30 imputations). Statistical analyses were conducted using Stata 17 software (Stata Corp, TX, 2021) and R Statistical Software (version 4.1.2; R Foundation for Statistical Computing, Vienna, Austria).

We also performed several sensitivity analyses: (1) including participants who had completed the questionnaire on demographic and socioeconomic characteristics, adherence to COVID-19 preventive measures, and health status, more than 60 days before and after their blood sample; (2) including a third age category (from 20 to 34 years old; based on the hypothesis that people in this category could have had more social interactions and therefore an increased risk of being infected) and (3) using a score computed from the preventive behaviours variables (hereafter, preventive behaviours score). The score goes from 0 to 4; one point for every “occasionally/rarely” answer to the questions on preventive behaviours. The higher the score, the less frequent the adherence to preventive behaviours.

Results

Characteristics of the sample

We included 13,291 respondents (53% females), with a mean age of 55.9 years (SD = 16.9). Characteristics of the participants are summarized in Table 1. Participants' characteristics across study periods and by cantons are detailed in Tables S1 and S2 (Additional file 1: Tables S1 and S2). Some 61% of participants were aged between 20 and 64 years and 39% were 65 years and older. 46% of

Table 1 Characteristics of participants (n = 13,291), Corona Immunitas study, Switzerland, May 2020—September 2021

Sociodemographic characteristics	
Sex	
Female	53%
Male	47%
Age group	
≥ 65	39%
20–64	61%
Children in the household	
No children	77%
One child	9%
More than one child	14%
Socioeconomic characteristics	
Educational level ^a	
Tertiary	46%
Secondary	48%
Primary	6%
Household income	
> CHF 9000	34%
CHF > 6000–9000	28%
CHF > 3000–6000	28%
CHF ≤ 3000	10%
Employment status	
Retired	38%
Outside the labour force ^b	10%
Self employed	10%
Employed	42%
Health status	
Body Mass Index	
< 18.5	3%
18.5–24.9	52%
25–29.9	33%
≥ 30	12%
Comorbidity score ^c	
0	53%
1	32%
≥ 2	15%
Smoking	
Non-smoker	84%
Smoker	16%
Preventive behaviours	
Physical distancing during previous 7 days	
Frequently	91%
Occasionally/rarely	9%
Staying at home during previous 7 days	
Frequently	69%
Occasionally/rarely	31%
Wearing mask during previous 7 days	
Frequently	83%
Occasionally/rarely	17%

Table 1 (continued)

Hygiene measures during previous 7 days	
Frequently	94%
Occasionally/rarely	6%

^aInternational Standard Classification of Education (ISCED)

^bOutside the labour force includes participants in training/studying and unemployed participants

^cComorbidity score goes from 0 to ≥ 2 and was calculated using the following possible answers: cancer; immunological diseases; cardiovascular diseases or diabetes or hypertension; respiratory diseases; allergies

participants were highly educated, 42% were employed and 23% lived with children. 47% had one or more comorbidities. In our sample people aged over 65 years were over-represented by design, and smokers, employed participants, households with one or more than one child, low-income households and people with only primary education were slightly underrepresented [25].

Seroprevalence estimates and trends

During period 1, seroprevalence was 3.7% (95% CI 2.1–4.9). It increased to 16.2% (95% CI 14.4–17.5) during period 2 and to 72.0% (95% CI 70.3–73.8) during period 3. Seroprevalence varied by age group, with higher estimates in

younger participants (20–64 years) during period 1 and in older participants (65 years and older) during period 3 (Additional file 1: Table S3). There were some regional variations between cantons (Table 2 and Fig. 2). During period 1, seroprevalence in cantons from the French and Italian speaking regions of Switzerland ranged from 3.0 to 7.7%, and in cantons from the German speaking regions from 2.1 to 5.0%. We found substantial differences between cantons during periods 2 and 3.

Factors associated with seropositivity

Table 3 shows the results of the multivariable models by study period. Information on missing data are reported in Tables S4 and S5 (Additional file1: Tables S4 and S5). Before the start of the vaccination campaign (period 1), participants aged between 20 and 64 years had a higher prevalence of seropositivity (PR = 2.32, 95% CI 1.03–5.22) compared to older participants. After the start of the vaccination campaign (period 3), participants aged 20–64 years old (PR = 0.85, 95% CI 0.78–0.93), with a low household income (PR = 0.75, 95% CI 0.68–0.82) or with an employment status different from retired had a lower prevalence of seropositivity compared to reference categories. Participants with a BMI of 25 or more (PR = 1.12, 95% CI 1.04–1.19) or with one or more comorbidities (PR = 1.12, 95% CI 1.06–1.18) had a higher prevalence

Table 2 Seroprevalence estimates^a (IgG anti Sars-CoV-2 Spike) by study period and canton, Corona Immunitas study, Switzerland, May 2020–September 2021

Time window	Period 1, n = 3402	Period 2, n = 5611	Period 3, n = 4278
	01/05/2020–31/10/2020	01/11/2020–15/05/2021	16/05/2021–31/09/2021
	% (95%CI)	% (95%CI)	% (95%CI)
National level	3.7 (2.1–4.9)	16.2 (14.4–17.5)	72.0 (70.3–73.8)
Basel-Landschaft	2.9 (1.3–5.4)	16.5 (13.4–19.9)	82.8 (78.0–87.3)
Basel-Stadt	5.0 (2.6–7.8)	19.7 (16.2–23.2)	77.2 (72.7–81.6)
Bern	NA	10.9 (7.4–14.7)	78.1 (74.1–82.0)
Fribourg	5.9 (3.2–9.1)	22.5 (18.7–26.6)	73.5 (68.4–78.4)
Grisons ^b	NA	15.7 (11.5–20.3)	43.2 (37.2–49.3)
Lucerne	NA	15.5 (11.7–19.7)	58.9 (54.4–63.6)
Neuchâtel	3.0 (1.4–5.4)	19.2 (15.4–23.1)	79.2 (74.8–83.2)
Saint Gallen ^b	NA	11.7 (7.8–16.5)	62.2 (56.6–68.0)
Ticino ^c	7.7 (5.3–10.3)	6.8 (4.1–9.7)	NA
Vaud	6.5 (3.8–9.8)	23.7 (20.3–27.1)	NA
Zurich	2.1 (1.0–3.6)	9.7 (6.7–13.0)	78.5 (74.3–82.5)

Samplings in Bern, Grisons, Lucerne and Saint Gallen started after period 1. Data for Ticino and Vaud period 3 were not available for the analyses presented in this study


IgG immunoglobulin G, NA not available

^aSeroprevalence was estimated using Bayesian regression adjusted for the antibody test sensitivity and specificity performances and weighted by age and sex of the general population of each canton

^bIn cantons Grisons and Saint Gallen, only participants aged from 20 to 64 years were tested

^cIn canton Ticino, during period 1, only participants aged from 20 to 64 were tested. During period 2 only data from people aged 65 years or more were available for these analyses

Fig. 2 Trends of seroprevalence estimates (IgG anti SARS-CoV-2 Spike) per canton and by age group, Corona Immunitas study, Switzerland, May 2020–September 2021



Note: estimates are reported with 95% CIs
 Abbreviations: BL= Basel-Landschaft; BS= Basel-Stadt; BE= Bern; FR= Fribourg; GR= Grisons; LU= Lucerne; NE= Neuchâtel; SG= Saint Gallen; TI= Ticino; VD= Vaud; ZU= Zürich

of seropositivity. However, all these differences disappeared upon adjustment for vaccination status in period 3 (percentages of vaccinated participants in period 3 are reported in additional file 1: Table S6).

None of the self-reported preventive behaviours (Table 4) were associated with seropositivity before the start of the vaccination campaign (period 1). In period 3, participants who reported to occasionally or rarely practice physical distancing (PR = 0.81, 95% CI 0.75–0.89), stay at home (PR = 0.94, 95% CI 0.90–0.98), wear a mask (PR = 0.76, 95% CI 0.70–0.84) and perform hygiene measures (PR = 0.79, 95% CI 0.72–0.87) had a lower prevalence of seropositivity compared to participants who frequently

adhered to preventive behaviours. All these differences disappeared after adjusting for vaccination status.

Sensitivity analyses gave similar results as the main analyses and results are shown in supplementary material (Additional file1: Tables S7–S10).

Discussion

Main findings

Seroprevalence in Switzerland rose sharply between May 2020 and September 2021, with some regional variations,

Table 3 Association of sociodemographic, socioeconomic characteristics and health status with SARS-CoV-2 seropositivity across study periods, Corona Immunitas study, Switzerland, May 2020–September 2021

Factor	Period 1, n = 3108 (01/05/2020–31/10/2020)	Period 2, n = 4969 (01/11/2020–15/05/2021)	Period 3, n = 2836 (16/05/2021–31/09/2021)	
	Model 1 ^a , PR (95%)	Model 1 ^a , PR (95%)	Model 1 ^a , PR (95%)	Model 2 ^b , PR (95%)
Sex				
Female	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Male	1.15 (0.82–1.62)	1.05 (0.92–1.20)	0.93 (0.89–0.98)	0.97 (0.94–1.00)
Age groups				
≥ 65	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
20–64	2.32 (1.03–5.22)	1.22 (0.96–1.54)	0.85 (0.78–0.93)	0.94 (0.89–0.99)
Children in the household				
No children	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
One child	0.71 (0.40–1.24)	1.20 (0.96–1.49)	0.90 (0.82–1.00)	0.97 (0.90–1.04)
More than one child	1.01 (0.64–1.60)	1.11 (0.90–1.35)	0.92 (0.85–0.99)	1.06 (0.99–1.12)
Educational level				
Tertiary	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Secondary	1.62 (1.12–2.35)	0.83 (0.72–0.96)	0.95 (0.91–0.99)	1.01 (0.98–1.04)
Primary	1.49 (0.59–3.79)	1.15 (0.89–1.50)	0.92 (0.82–1.03)	1.01 (0.93–1.10)
Household income				
> CHF 9000	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
CHF > 6000–9000	0.72 (0.44–1.19)	1.07 (0.90–1.27)	0.88 (0.83–0.93)	0.99 (0.95–1.03)
CHF > 3000–6000	0.76 (0.46–1.27)	1.25 (1.04–1.51)	0.83 (0.78–0.88)	0.97 (0.94–1.01)
CHF ≤ 3000	0.79 (0.38–1.65)	0.94 (0.71–1.26)	0.75 (0.68–0.82)	0.94 (0.89–1.01)
Employment status				
Retired	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Outside the labour force ^b	1.09 (0.46–2.60)	0.69 (0.54–0.89)	0.84 (0.72–0.97)	1.00 (0.90–1.10)
Self employed	1.10 (0.50–2.41)	0.68 (0.49–0.95)	0.78 (0.69–0.88)	0.97 (0.90–1.06)
Employed	0.56 (0.25–1.26)	0.81 (0.63–1.04)	0.84 (0.77–0.93)	1.00 (0.95–1.06)
Body Mass Index				
18.5–24.9	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
< 18.5	0.49 (0.12–1.96)	1.07 (0.70–1.63)	0.99(0.86–1.14)	1.04 (0.93–1.16)
25–29.9	0.72 (0.49–1.07)	1.12 (0.97–1.30)	1.08(1.03–1.13)	1.04 (1.00–1.07)
≥ 30	0.67 (0.38–1.17)	1.18 (0.97–1.44)	1.12(1.04–1.19)	1.04 (1.00–1.09)
Comorbidity score^d				
0	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
1	1.23 (0.82–1.79)	0.95 (0.82–1.10)	1.08(1.03–1.13)	1.01 (0.98–1.04)
≥ 2	1.26 (0.74–2.16)	1.24 (1.04–1.48)	1.12(1.06–1.18)	1.00 (0.97–1.03)
Smoking				
Non-smoker	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Smoker	0.80 (0.49–1.29)	0.81 (0.66–0.99)	0.93 (0.86–1.00)	0.97 (0.92–1.01)

^aModel adjusted for: sex, age, educational level, body mass index, income, employment status, children in the household, comorbidity score and smoking habit

^bModel additionally adjusted for vaccination status

^cOutside the labour force includes participants in training/studying and not employed participants

^dComorbidity score goes from 0 to ≥ 2 and was calculated using the following possible answers: cancer; immunological diseases; cardiovascular diseases or diabetes or hypertension; respiratory diseases; allergies

from 3.7% (95% CI 2.1–4.9) in May–October 2020, to 16.2% (95% CI 14.4–17.5) between November 2020 and mid-May 2021, and finally 72.0% (95% CI 70.3–73.8) between

mid-May and September 2021. Before the start of the vaccination campaign, seropositivity differed by age but not by other factors. After the start of the vaccination campaign,

Table 4 Association of recommended preventive behaviours with SARS-CoV-2 seropositivity across study periods, Corona Immunitas study, Switzerland, May 2020–September 2021

Factor	Period 1, n=2151 (01/05/2020–31/10/2020)	Period 2, n=4969 (01/11/2020–15/05/2021)	Period 3, n=2836 (16/05/2021–31/09/2021)	
	Model 1 ^a , PR (95%)	Model 1 ^a , PR (95%)	Model 1 ^a , PR (95%)	Model 2 ^b , PR (95%)
Physical distancing during previous 7 days				
Frequently	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Occasionally/rarely	1.25 (0.61–2.59)	1.52 (1.18–1.96)	0.81 (0.75–0.89)	0.97 (0.92–1.02)
Staying at home during previous 7 days				
Frequently	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Occasionally/rarely	1.43 (0.86–2.37)	1.13 (0.96–1.33)	0.94 (0.90–0.98)	1.02 (0.99–1.05)
Wearing mask during previous 7 days				
Frequently	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Occasionally/rarely	0.68 (0.41–1.13)	1.06 (0.78–1.43)	0.76 (0.70–0.84)	0.96 (0.91–1.02)
Hygiene measures during previous 7 days				
Frequently	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Occasionally/rarely	0.97 (0.31–3.02)	0.88 (0.62–1.25)	0.79 (0.72–0.87)	1.01 (0.94–1.08)

Data from Ticino and data from Vaud period 1 were not included because not harmonizable with data from other sites

^aModel adjusted for sex, age, educational level, body mass index, income, employment status, children in the household, comorbidity score and smoking habit

^bModel additionally adjusted for vaccination status

seropositivity was higher among participants over 65 years, with a high income, retired, overweight or obese, or with other comorbidities, due to a higher vaccination uptake. Seropositivity was lower in participants with lower adherence to preventive measures, due to a reduced propensity for vaccination uptake.

Comparison with other studies

This study's findings describe the evolution of the SARS-CoV-2 spread and of population immunological status in the first phases of the COVID-19 pandemic in several cantons of Switzerland, accounting for under-ascertainment and differences in testing strategies across Swiss cantons. European seroprevalence estimates varied widely during the pandemic, depending on study populations, study periods and methods used. However, our seroprevalence estimates were roughly similar to estimates found by other seroprevalence surveys in the same periods in other Swiss cantons [24, 26] and to pooled estimates from other European high-income countries [9]. We found some variations in seroprevalence estimates between cantons during period 1, with estimates ranging from 3.0 to 6.5% in the French speaking cantons, being 7.7% in Ticino, and ranging from 2.1 to 5.0% in German speaking cantons. These results are particularly interesting in light of the fact that, especially at the beginning of the pandemic, comparisons between studies were hindered by differences in study designs. We also found substantial differences during period 2 and 3. However, these results

are difficult to interpret, since seroprevalence estimates were strongly influenced by vaccination rates during these periods, and differences in testing periods could have resulted in different estimates.

During the first period of this study, i.e., before the start of the vaccination campaign, we found a higher prevalence of seropositivity in participants aged between 20 and 64 years compared to those aged 65 years and older. Other studies showed higher seroprevalence in younger adults [10–13] compared to older population's groups, and this could be due to the fact that younger populations were considered at lower risk of severe illness and therefore could have had more social interactions. No other factor was associated with seropositivity during the first period of this study, despite several studies showing differences in seropositivity according to socioeconomic characteristics (e.g., higher seroprevalence in people with lower income or lower educational level) [10], health behaviours (e.g., higher seroprevalence in smokers vs non-smokers) [11, 13] or other sociodemographic characteristics (e.g., higher seroprevalence in households with more than one child) [13]. The higher prevalence of seropositivity found during the third period of this study among participants aged over 65 years, overweight or obese, retired and with other comorbidities, was due to a higher vaccination rate in these subgroups. These results were expected, since the vaccination campaign in Switzerland prioritised people with a higher risk of severe illness and death (i.e., older people and people with comorbidities or a high BMI) [27]. Having a high household income was also associated with

higher seropositivity due to a higher vaccination uptake. This finding is consistent with other studies conducted in Switzerland [28] and elsewhere [29, 30].

Regarding preventive behaviours, despite several personal and social preventive measures associated with a reduction in the incidence of COVID-19 [21, 31], we did not find associations between adherence to preventive behaviours and seropositivity before the start of the vaccination campaign (period 1). This result could be due to selection bias, as people who adhered less to preventive measures were also less likely to participate in this study. Another hypothetical explanation is that people who did not frequently adhere to the recommended measures benefited from the collective adherence to those same measures, or from the low seroprevalence in period 1. During the last study period, we found a lower prevalence of seropositivity in people with lower adherence to recommended preventive behaviours, especially in participants who less frequently wore masks. This was explained by a lower vaccination uptake in these groups. Other studies investigated the associations between willingness to receive the COVID-19 vaccine and adherence to preventive behaviours [32], showing that people who are more prone to follow prevention recommendations are also more likely to get vaccinated. Overall, the associations between risk factors and seroprevalence during period 2 were difficult to interpret because period 2 included blood sample collected both before and after the vaccination campaign and because, during the first months of the vaccination campaign, self-reported information on vaccination status was less reliable, due to organizational difficulties in promptly modifying the questionnaires to include questions on vaccination status.

Strengths and limitations

This study has some limitations. Overall, the participation rate was moderate (21%). Moreover, despite random representative samples of the population being invited, selection bias is possible, with a higher participation rate of highly educated participants compared to the Swiss general population. Further, seroprevalence could be underestimated due to waning immunity [33], people failing to produce antibodies [34] and due to the fact that we only measured the amount of anti-SARS-CoV-2 IgGs, without assessing other types of antibodies. We were therefore not able to distinguish between infection-related and vaccination-related antibodies. Information bias is also possible, since the information collected through the questionnaire was self-reported. The key strengths of our study include the use of a large population-based sample covering a significant proportion of the country and with repeated samplings over time, the use of a previously validated test with high sensitivity and specificity,

and post-stratification weights to account for differences in sex and age.

Conclusions

Seroprevalence in Switzerland has increased sharply over time, also thanks to the increasing vaccination coverage, with some regional differences. After the vaccination campaign, no differences between subgroups were observed.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s15010-023-02011-0>.

Acknowledgements Corona Immunitas Research Group: The following are members of Corona Immunitas Research Group (including the authors of the present article), listed in alphabetical order: Emiliano Albanese, MD, PhD (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Rebecca Amati, PhD (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland) Antonio Amendola, Msc (Department of Business Economics, Health and Social Care (DEASS), University of Applied Sciences & Arts of Southern Switzerland (SUPSI), Switzerland; Alexia Anagnostopoulos, MD MPH (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Daniela Anker, PhD (Population Health Laboratory (#PopHealthLab), University of Fribourg, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland); Anna Maria Annoni, Msc (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Hélène Aschmann, PhD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Andrew Azman, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Antoine Bal, MSc (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Tala Ballouz, MD MPH (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Hélène Baysson, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Kleona Bezani, Msc (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Annette Blattmann (Cantonal Hospital St. Gallen, Clinic for Infectious Diseases and Hospital Epidemiology, St. Gallen, Switzerland); Patrick Bleich (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Murielle Bochud, MD, PhD (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Patrick Bodenmann, MD, Msc (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Gaëlle Bryand Rumley, MSc (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Peter Buttaroni (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Audrey Butty, MD (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Anne Linda Camerini, PhD (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Arnaud Chiolerio, MD, PhD (Population Health Laboratory (#PopHealthLab), University of Fribourg, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland;

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada); Patricia Oriaziz Chocano-Bedoya, MD, PhD (Institute of Primary Health Care (BIHAM), University of Bern; Population Health Laboratory (#PopHealthLab), University of Fribourg, Switzerland); Prune Collombet (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Laurie Corna, PhD (Department of Business Economics, Health and Social Care (DEASS), University of Applied Sciences & Arts of Southern Switzerland (SUPSI), Switzerland); Luca Crivelli, PhD (Department of Business Economics, Health and Social Care (DEASS), University of Applied Sciences & Arts of Southern Switzerland (SUPSI), Switzerland); Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Stéphane Cullati, PhD (Population Health Laboratory (#PopHealthLab), University of Fribourg, Switzerland); Department of Readaptation and Geriatrics, University of Geneva, Switzerland); Valérie D'Acremont, MD, PhD (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Swiss Tropical and Public Health Institute, Basel, Switzerland); Diana Sofia Da Costa Santos (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Agathe Deschamps (Cantonal Medical Service Neuchâtel); Paola D'Ippolito (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Anja Domenghino, Dr. med. (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Richard Dubos, MSc (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Roxane Dumont, MSc (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Olivier Duperrex, MD, MSc (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Julien Dupraz, MD, MAS (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Malik Egger (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Emna El-May, MSc (Population Health Laboratory (#PopHealthLab), University of Fribourg, Switzerland); Nacira El Merjani (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Nathalie Engler (Cantonal Hospital St. Gallen, Clinic for Infectious Diseases and Hospital Epidemiology, St. Gallen, Switzerland); Adina Mihaela Epure, MD (Population Health Laboratory (#PopHealthLab), University of Fribourg, Switzerland); Lukas Erksam (Institute of Primary Health Care (BIHAM), University of Bern, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern); Sandrine Estoppey (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Marta Fadda, PhD (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Vincent Faivre (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Jan Fehr, MD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Andrea Felappi (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Maddalena Fiordelli, PhD (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Antoine Flahault, MD, PhD (Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland); Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Luc Fornerod, MAS (Observatoire valaisan de la santé (OVS), Sion, Switzerland); Cristina Frago Corti, PhD (Department of environment construction and design (DACD), University of Applied Sciences & Arts of Southern Switzerland (SUPSI), Switzerland); Natalie Francioli (Unit of Population Epidemiology, Division of Primary Care Medicine,

Geneva University Hospitals, Geneva, Switzerland); Marion Frangville, MSc (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Irène Frank, PhD (Luzerner Kantonsspital, Spitalstrasse, 6000 Luzern 16); Giovanni Franscella, MSc (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Anja Frei, PhD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Marco Geigges, PhD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Semira Gonseth Nusslé, MD, MSc (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Clément Graindorge, MD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Idris Guessous, MD, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Erika Harju, PhD (Department of Health Sciences and Medicine, University of Lucerne, Frohburgstrasse 3, 6002 Lucerne); Séverine Harnal (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Medea Imboden, PhD (Swiss Tropical and Public Health Institute, Department of Epidemiology and Public Health, Basel, Switzerland); University of Basel, Basel, Switzerland); Emilie Jendly (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Ayoung Jeong, PhD (Swiss Tropical and Public Health Institute, Department of Epidemiology and Public Health, Basel, Switzerland); University of Basel, Basel, Switzerland); Christian R. Kahlert, MD (Cantonal Hospital St. Gallen, Clinic for Infectious Diseases and Hospital Epidemiology, St. Gallen, Switzerland); Children's Hospital of Eastern Switzerland, Infectious Diseases and Hospital Epidemiology, St. Gallen, Switzerland); Laurent Kaiser, MD, PhD (Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland); Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland); Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Laurent Kaufmann (Service de La Santé Publique, Canton de Neuchâtel, Neuchâtel, Switzerland); Marco Kaufmann PhD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Dirk Keidel, MSc (Swiss Tropical and Public Health Institute, Department of Epidemiology and Public Health, Basel, Switzerland); University of Basel, Basel, Switzerland); Simone Kessler (Cantonal Hospital St. Gallen, Clinic for Infectious Diseases and Hospital Epidemiology, St. Gallen, Switzerland); Philipp Kohler, MD, MPH (Cantonal Hospital St. Gallen, Clinic for Infectious Diseases and Hospital Epidemiology, St. Gallen, Switzerland); Christine Krähenbühl (Luzerner Kantonsspital, Spitalstrasse, 6000 Luzern 16); Susi Kriemler, MD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Julien Lamour (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Sara Levati, PhD (Department of Business Economics, Health and Social Care (DEASS), University of Applied Sciences & Arts of Southern Switzerland (SUPSI), Switzerland); Pierre Lescuyer, PhD (Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland); Andrea Loizeau, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Elsa Lorthe, RM, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Chantal Luedi (Department Health Sciences and Medicine, University of Lucerne, Frohburgstrasse 3, 6002 Lucerne); Jean-Luc Magnin, PhD (Laboratory, HFR-Fribourg, Fribourg, Switzerland); Chantal Martinez (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Eric Masserey (Cantonal Medical Office, General Health Department, Canton of Vaud, Switzerland); Dominik Menges, MD MPH (Epidemiology,

Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Gisela Michel, PhD (Department of Health Sciences and Medicine, University of Lucerne, Frohburgstrasse 3, 6002 Lucerne); Rosalba Morese, PhD (Faculty of Communication, Culture and Society, Università della Svizzera italiana, Lugano, Switzerland); Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland); Nicolai Mösli (Swiss TPH, Basel, Switzerland; University of Basel, Basel, Switzerland); Natacha Noël (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Daniel Henry Paris, MD PhD (Swiss TPH, Basel, Switzerland; University of Basel, Basel, Switzerland); Jérôme Pasquier, PhD (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Francesco Pennacchio, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Stefan Pfister, PhD (Laboratory, HFR-Fribourg, Fribourg, Switzerland); Giovanni Piumatti, PhD (Fondazione Agnelli, Turin, Italy); Géraldine Poulain (Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland); Nicole Probst-Hensch, Dr. phil. II, PhD, MPH (Swiss Tropical and Public Health Institute, Department of Epidemiology and Public Health, Basel, Switzerland; University of Basel, Basel, Switzerland); Caroline Pugin (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Milo Puhan, MD, PhD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Nick Pullen, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Thomas Radtke, PhD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Manuela Rasi, MScN (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Aude Richard (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Institute of Global Health, University of Geneva, Switzerland); Viviane Richard, MSc (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Claude-François Robert (Cantonal Medical Service Neuchâtel); Pierre-Yves Rodondi, MD (Institute of Family Medicine, University of Fribourg, Fribourg, Switzerland); Nicolas Rodondi, MD, MAS (Institute of Primary Health Care (BIHAM), University of Bern; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern); Serena Sabatini, PhD (Institute of Public Health (IPH), Università della Svizzera italiana, Lugano, Switzerland); Khadija Samir (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Javier Sanchis Zozaya, MD (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Virginie Schlüter, MAS (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Alexia Schmid, MSc (Institute of Family Medicine, University of Fribourg, Fribourg, Switzerland); Valentine Schneider (Cantonal Medical Service Neuchâtel); Maria Schüpbach (Institute of Primary Health Care (BIHAM), University of Bern, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern); Nathalie Schwab (Institute of Primary Health Care (BIHAM), University of Bern, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern); Claire Semaani (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Alexandre Speierer (Institute of Primary Health Care (BIHAM), University of Bern; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern); Amélie Steiner-Dubuis (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Silvia Stringhini, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva,

Switzerland); Stefano Tancredi, MD (Population Health Laboratory (#PopHealth-Lab), University of Fribourg, Switzerland); Stéphanie Testini (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Julien Thabard (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Mauro Tonolla, PD PhD (Department of environment construction and design (DACD), University of Applied Sciences & Arts of Southern Switzerland (SUPSI), Switzerland); Nicolas Troillet, MD, MSc (Office du médecin cantonal, Sion, Switzerland); Agne Ulyte, MD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Sophie Vassaux (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland); Thomas Vermes, MSc (Swiss Tropical and Public Health Institute, Department of Epidemiology and Public Health, Basel, Switzerland; University of Basel, Basel, Switzerland); Jennifer Villers, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Viktor von Wyl (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Cornelia Wagner, MSc (Population Health Laboratory (#PopHealthLab), University of Fribourg, Switzerland); Rylana Wenger (Institute of Primary Health Care (BIHAM), University of Bern, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern); Erin West, PhD (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Ania Wisniak, MD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland); Melissa Witzig, MSc (Swiss Tropical and Public Health Institute, Department of Epidemiology and Public Health, Basel, Switzerland; University of Basel, Basel, Switzerland); María-Eugenia Zaballa, PhD (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland); Kyra Zens, PhD, MPH (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Claire Zuppinger (Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland).

Author contributions All authors designed the study. ST and SC analysed the data. ST drafted the manuscript with contributions of AC, JF and SC. All co-authors contributed to the data acquisition, interpretation and revised the first draft of the manuscript. All authors approved the final version of the manuscript before submission.

Funding Open access funding provided by University of Fribourg. The Directorate of SSPH+ is responsible for the coordination, communication, fundraising, and legal aspects of the population-based studies and the central program of Corona Immunitas. This study was funded by several sources that includes, but is not limited to, SSPH+ and the Swiss Federal Office of Public Health. Funders had no influence on the design, conduct, analyses and publications.

Data availability Deidentified individual participant data underlying the findings of this study will be available for researchers submitting a methodologically sound proposal to achieve the aims of the proposal after the publication of this article. Access to data requires contacting Corona Immunitas.

Declarations

Conflict of interest The authors declare no competing interests.

Ethical approval and consent to participate The Ethics Committees of the various cantons approved this study (Cantons of Zurich, St. Gallen, Grisons, Fribourg, Lucerne, Bern, Neuchâtel: BASEC 2020-

01247, Canton of Vaud: BASEC 2020-00887, Canton of Basel-City and Basel-Country: BASEC 2020-00927, Canton of Ticino: BASEC 2020-01514). The subjects of the study provided written informed consent (included in submission) prior to their participation in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Byambasuren O, Dobler CC, Bell K, Rojas DP, Clark J, McLaws ML, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. *PLoS One*. 2021;16: e0248946.
- Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. *Proc Natl Acad Sci USA*. 2021;118(34):e2109229118
- Alene M, Yismaw L, Assemie MA, Ketema DB, Mengist B, Kassie B, et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: a systematic review and meta-analysis. *PLoS One*. 2021;16: e0249090.
- Sharfstein JM, Becker SJ, Mello MM. Diagnostic testing for the novel coronavirus. *JAMA*. 2020;323:1437–8.
- Tancredi S, Anker D, Rosella L, Chioloro A. Elimination of covid-19: beware of surveillance bias. *Bmj*. 2021;374:n2126.
- Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. *PLoS One*. 2021;16: e0252617.
- Rostami A, Sepidarkish M, Fazlzadeh A, Mokdad AH, Sattarnezhad A, Esfandyari S, et al. Update on SARS-CoV-2 seroprevalence: regional and worldwide. *Clin Microbiol Infect*. 2021;27:1762–71.
- Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. *J Hosp Infect*. 2021;108:120–34.
- Bergeri I, Whelan M, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022. *medRxiv*. 2022:2021.12.14.21267791.
- Basto-Abreu A, Carnalla M, Torres-Ibarra L, Romero-Martínez M, Martínez-Barnetteche J, López-Martínez I, et al. Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico. *Nat Commun*. 2022;13:589.
- Richard A, Wisniak A, Perez-Saez J, Garrison-Desany H, Petrovic D, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study. *Scand J Public Health*. 2022;50:124–35.
- Vos ERA, den Hartog G, Schepp RM, Kaaijk P, van Vliet J, Helm K, et al. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave. *J Epidemiol Community Health*. 2021;75:489–95.
- Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, et al. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multi-cohort study. *Int J Epidemiol*. 2021;50:1458–72.
- Beaumont A, Durand C, Ledrans M, Schwoebel V, Noel H, Le Strat Y, et al. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study. *BMJ Open*. 2021;11: e053201.
- Abaluck J, Kwong LH, Styczynski A, Haque A, Kabir MA, Bates-Jefferys E, et al. Impact of community masking on COVID-19: a cluster-randomized trial in Bangladesh. *Science*. 2022;375: eabi9069.
- West EA, Anker D, Amati R, Richard A, Wisniak A, Butty A, et al. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. *Int J Public Health*. 2020;65:1529–48.
- World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, 17 March 2020. Geneva: World Health Organization; 2020. Contract No.: WHO/2019-nCoV/Seroepidemiology/2020.1.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377–81.
- Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in SARS-CoV-2 Spike versus nucleoprotein antibody responses impact the estimates of infections in population-based seroprevalence studies. *J Virol*. 2021;95(3):e01828–20.
- Galmiche S, Charmet T, Schaeffer L, Paireau J, Grant R, Chény O, et al. Exposures associated with SARS-CoV-2 infection in France: a nationwide online case-control study. *Lancet Reg Health Eur*. 2021;7: 100148.
- Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. *BMJ*. 2021;375: e068302.
- Blankenberger J, Kaufmann M, Albanese E, Amati R, Anker D, Camerini AL, et al. Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas. *BMC Med*. 2022;20:233.
- World Health Organization. WHO global infoBase team. The SuRF Report 2. Surveillance of chronic disease Risk Factors: Country-level data and comparable estimates. Geneva; 2005.
- Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020;396:313–9.
- Federal Statistical Office (FSO). Available from: <https://www.bfs.admin.ch/bfs/en/home/statistics.html>.
- Stringhini S, Zaballa ME, Pullen N, Perez-Saez J, de Mestral C, Loizeau AJ, et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. *Euro Surveill*. 2021. <https://doi.org/10.2807/1560-7917.ES.2021.26.43.2100830>.
- Federal Office of Public Health. Available from: <https://www.bfs.admin.ch/bfs/en/home/statistics.html>.
- Heiniger S, Schliek M, Moser A, von Wyl V, Höglinger M. Differences in COVID-19 vaccination uptake in the first 12 months of vaccine availability in Switzerland—a prospective cohort study. *Swiss Med Wkly*. 2022;152: w30162.

29. Bayati M, Noroozi R, Ghanbari-Jahromi M, Jalali FS. Inequality in the distribution of Covid-19 vaccine: a systematic review. *Int J Equity Health*. 2022;21:122.
30. Williams AM, Clayton HB, Singleton JA. Racial and ethnic disparities in COVID-19 vaccination coverage: the contribution of socioeconomic and demographic factors. *Am J Prev Med*. 2022;62:473–82.
31. Iezadi S, Gholipour K, Azami-Aghdash S, Ghiasi A, Rezapour A, Pourasghari H, et al. Effectiveness of non-pharmaceutical public health interventions against COVID-19: a systematic review and meta-analysis. *PLoS One*. 2021;16: e0260371.
32. Lam CN, Kaplan C, Saluja S. Relationship between mask wearing, testing, and vaccine willingness among Los Angeles County adults during the peak of the COVID-19 pandemic. *Transl Behav Med*. 2022;12:480–5.
33. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. *Nature*. 2021;591:639–44.
34. Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, et al. Predictors of nonseroconversion after SARS-CoV-2 infection. *Emerg Infect Dis*. 2021;27(9):2454–8.

Authors and Affiliations

Stefano Tancredi¹ · Arnaud Chiolero^{1,2,3} · Cornelia Wagner¹ · Moa Lina Haller^{3,4} · Patricia Chocano-Bedoya^{1,3} · Natalia Ortega^{1,3} · Nicolas Rodondi^{3,4} · Laurent Kaufmann⁵ · Elsa Lorthe⁶ · H el ene Baysson^{6,7} · Silvia Stringhini^{6,7,8} · Gisela Michel⁹ · Chantal L udi⁹ · Erika Harju^{9,10} · Irene Frank¹⁰ · Medea Imboden^{11,12} · Melissa Witzig^{11,12} · Dirk Keidel^{11,12} · Nicole Probst-Hensch^{11,12} · Rebecca Amati¹³ · Emiliano Albanese¹³ · Laurie Corna¹⁴ · Luca Crivelli¹⁴ · Julia Vincentini¹⁵ · Semira Gonseth Nussl e¹⁵ · Murielle Bochud¹⁵ · Val erie D'Acremont^{11,15} · Philipp Kohler¹⁶ · Christian R. Kahlert^{16,17} · Alexia Cusini¹⁸ · Anja Frei¹⁹ · Milo A. Puhan¹⁹ · Marco Geigges¹⁹ · Marco Kaufmann¹⁹ · Jan Fehr¹⁹ · St ephane Cullati^{1,20} on behalf of the Corona Immunitas Research Group

¹ Population Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700 Fribourg, Switzerland

² School of Population and Global Health, McGill University, Montreal, Canada

³ Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

⁴ Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

⁵ Cantonal Public Health Service of the Canton of Neuch atel, Neuch atel, Switzerland

⁶ Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland

⁷ Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland

⁸ University Center for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland

⁹ Department Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland

¹⁰ Clinical Trial Unit, Lucerne Cantonal Hospital, Lucerne, Switzerland

¹¹ Swiss Tropical and Public Health Institute, Allschwil, Switzerland

¹² University of Basel, Basel, Switzerland

¹³ Institute of Public Health, Faculty of Biomedical Sciences, Universit a Della Svizzera Italiana, Lugano, Switzerland

¹⁴ Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland

¹⁵ Center for Primary Care and Public Health (Unisant e), University of Lausanne, Lausanne, Switzerland

¹⁶ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland

¹⁷ Department of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland

¹⁸ Division of Infectious Diseases, Cantonal Hospital of Grisons, Chur, Switzerland

¹⁹ Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

²⁰ Department of Readaptation and Geriatrics, University of Geneva, Geneva, Switzerland